Will New Anti-eosinophilic Drugs Be Useful in Asthma Management?

Recently there has been great interest in the development of precision medicines that target a specific underlying disease mechanism so that responders will have a better therapeutic response and less adverse effects compared with the nonspecific therapies that are currently used. Peter Barnes is Professor of Thoracic Medicine and Head of Respiratory Medicine at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London.

 

Publication

Image courtesy of interviewee

Leave a Reply

Your email address will not be published.

×
Guest visitors to the Faculti website can view any insight monthly. You have insight(s) remaining for this month

Register for free as an individual and view thousands of insights in our archive today or subscribe for subject access.

You may already have institutional access to Faculti. Please access Faculti using your institution credentials.

Copyright © Faculti Media Limited 2022. All rights reserved.
error:

Add the Faculti Web App to your Mobile or Desktop homescreen

Install
×